Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

To investigate the combined enhancing effects of microbubble-contrast SonoVue and oxytocin on high-intensity focused ultrasound (HIFU) ablation of adenomyosis.

Who Took Part

The study group was 330 patients.

330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.

The clinical data, treatment results, and complications were analyzed.

How the Study Was Run

The design is described as randomized.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In group C, HIFU ablation was started one minute after SonoVue injection.

In group D, neither oxytocin nor SonoVue was applied.

What Was Measured

Topics PubMed links to this paper include Adenomyosis, Contrast Media, High-Intensity Focused Ultrasound Ablation, Microbubbles, Oxytocin, Phospholipids and Sulfur Hexafluoride.

Author keywords: SonoVue.

What This Means in Plain Language

The paper is a randomized study of Oxytocin in 330 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group), a journal based in England.

More context: the Oxytocin compound page, all human trials.